Menu
← Oncology Approval Tracker
FDA DECISION ·
Tafinlar + Mekinist
dabrafenib plus trametinib · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients age six or older with BRAF V600E-mutated unresectable or metastatic solid tumors progressing after prior treatment and without satisfactory alternatives. The indication excludes colorectal cancer.
LAMPGEN ANALYSIS
Why it matters
This BRAF/MEK approval spans tumor types while retaining a colorectal exclusion.
What research teams should watch
Confirm the exact BRAF variant and tumor type and document the prior regimen and remaining alternatives.
PRIMARY RECORDS